Advertisement

Osteoporosis International

, Volume 22, Issue 2, pp 529–539 | Cite as

Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment

  • M. L. BianchiEmail author
  • L. Morandi
  • E. Andreucci
  • S. Vai
  • J. Frasunkiewicz
  • R. Cottafava
Original Article

Abstract

Summary

Boys with Duchenne muscular dystrophy often have reduced bone mass and increased fracture risk. In this prospective study on 33 patients, calcifediol (25-OH vitamin D3) plus adjustment of dietary calcium to the recommended dose reduced bone resorption, corrected vitamin D deficiency, and increased bone mass in about two-thirds of cases.

Introduction

Low BMC and BMD and bone metabolism alterations are frequent in boys with Duchenne muscular dystrophy (DMD), especially now that long-term glucocorticosteroid (GC) treatment is the standard of care. This prospective study was designed to evaluate the effects of a first-line treatment (25-OH vitamin D3 [calcifediol] plus adjustment of dietary calcium to the recommended daily dose) on bone.

Methods

Thirty-three children with DMD on GC treatment were followed for 3 years: one of observation and two of treatment. Main outcome: spine and total body BMC and BMD increase; secondary outcome: changes in bone turnover markers (C-terminal [CTx] and N-terminal [NTx] telopeptides of procollagen type I; osteocalcin [OC]).

Results

During the observation year, BMC and BMD decreased in all patients. At baseline and after 12 months, serum CTx and urinary NTx were higher than normal; OC and parathyroid hormone at the upper limit of normal; 25-OH vitamin D3 significantly lower than normal. After 2 years of calcifediol and calcium-rich diet, BMC and BMD significantly increased in over 65% of patients, and bone metabolism parameters and turnover markers normalized in most patients (78.8%). During the observation year, there were four fractures in four patients, while during the 2 years of treatment there were two fractures in two patients.

Conclusions

Calcifediol plus adequate dietary calcium intake seems to be an effective first-line approach that controls bone turnover, corrects vitamin D deficiency, and increases BMC and BMD in most patients with DMD. Lack of response seems related to persistently high bone turnover.

Keywords

Bone density Bone turnover Calcium Fractures Duchenne muscular dystrophy Vitamin D 

Notes

Conflict of interests

None.

Funding

None.

Authors’ contributions

Drs. Bianchi and Morandi had full access to all the data in the study and take responsibility for their integrity and for the accuracy of data analysis.

Study design: Bianchi, Morandi

Data acquisition: Bianchi, Morandi, Andreucci, Vai, Frasunkiewicz

Data analysis and interpretation: Bianchi, Morandi

Drafting of manuscript: Bianchi

Revision of the manuscript: Bianchi, Morandi, Andreucci, Vai, Frasunkiewicz

Statistical analysis: Bianchi

Dietary evaluation: Cottafava

References

  1. 1.
    Hoffman EP, Brown RH, Kunkel IM (1987) Dystrophin, the protein product of the Duchenne muscular dystrophy locus. Cell 51:919–928CrossRefPubMedGoogle Scholar
  2. 2.
    Manzur AY, Kuntzer T, Pike M, Swan AV (2008) Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 23(1):CD003725. doi: 10.1002/14651858.CD003725.pub3 Google Scholar
  3. 3.
    Jones J, Ponsonby AL, Smith BJ, Carmichael A (2000) Asthma, inhaled corticosteroid use, and bone mass in prepubertal children. J Asthma 37:603–611CrossRefPubMedGoogle Scholar
  4. 4.
    Naganathan V, Jones J, Nash P, Nicholson G, Eisman J, Sambrook PN (2000) Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Int Med 160:2917–2922CrossRefGoogle Scholar
  5. 5.
    Bianchi ML (2002) Glucorticoids and bone: some general remarks and some special observations in pediatric patients. Calcif Tissue Int 70:384–390CrossRefPubMedGoogle Scholar
  6. 6.
    Bianchi ML, Mazzanti A, Galbiati E, Saraifoger S, Dubini A, Cornelio F, Morandi L (2003) Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int 14:761–767CrossRefPubMedGoogle Scholar
  7. 7.
    Società Italiana di Nutrizione Umana, Livelli di assunzione giornalieri raccomandati di nutrienti per la popolazione italiana (LARN) SINU, Roma (Italy) 1996.Google Scholar
  8. 8.
    Food and Nutrition Board, Institute of Medicine of the National Academies. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. National Academies Press, Washington D.C. (USA), 2005.Google Scholar
  9. 9.
    Leclercq C, Ferro-Luzzi A (1991) Total and domestic consumption of salt and their determinants in three regions of Italy. Eur J Clin Nutr 45:151–9PubMedGoogle Scholar
  10. 10.
    Leclercq C, Piccinelli R, Arcella D, Le Donne C (2004) Food consumption and nutrient intake in a sample of Italian secondary school students: results from the INRAN-RM-2001 food survey. Int J Food Sci Nutr 55:265–77CrossRefPubMedGoogle Scholar
  11. 11.
    Leclercq C, Arcella D, Piccinelli R, Sette S, Le Donne C, Turrini A, INRAN-SCAI 2005-06 Study Group (2009) The Italian National Food Consumption Survey INRAN-SCAI 2005-06: main results in terms of food consumption. Public Health Nutr 12:2504–32CrossRefPubMedGoogle Scholar
  12. 12.
    Fantuzzi AL, Chiuchiù MP, Bedogni G (2004) Atlante fotografico delle porzioni degli alimenti. Istituto Scotti Bassani, Milano (Italy)Google Scholar
  13. 13.
    Bertoli S, Petroni ML, Pagliato E, Mora S, Weber G, Chiumello G, Testolin G (2005) Validation of food frequency questionnaire for assessing dietary macronutrients and calcium intake in Italian children and adolescents. J Pediatr Gastroenterol Nutr 40:555–60CrossRefPubMedGoogle Scholar
  14. 14.
    Dietosystem. Terapia alimentare. DS Medica, DS Medi Group SPA, Milano (Italy), 2005.Google Scholar
  15. 15.
    Turrini A, Leclercq C, D'Amicis A (1999) Patterns of food and nutrient intakes in Italy and their application to the development of food-based dietary guidelines. Br J Nutr 81(Suppl 2):S83–9CrossRefPubMedGoogle Scholar
  16. 16.
    Marletta L, Carnovale E (2001) Tabelle di composizione degli alimenti. Aggiornamento 2000. Edra, Milano (Italy)Google Scholar
  17. 17.
    Carter DR, Bouxsein ML, Marcus R (1992) New approaches for interpreting projected bone densitometry data. J Bone Miner Res 7:137–135CrossRefPubMedGoogle Scholar
  18. 18.
    Kröger H, Kotaniemi A, Vainio P, Alhava E (1992) Bone densitometry of spine and femur in children by dual-energy X-ray absorptiometry. Bone Miner 17:75–85CrossRefPubMedGoogle Scholar
  19. 19.
    Taylor A, Konrad PT, Norman ME, Harcke HT (1997) Total body mineral density in young children: influence of head bone mineral density. J Bone Miner Res 12:652–655CrossRefPubMedGoogle Scholar
  20. 20.
    Medical Research Council (1976) Aids to the investigation of peripheral nerve injuries. Her Majesty's Stationery Office, LondonGoogle Scholar
  21. 21.
    Cornelio F, Dworzak F, Morandi L (1984) Therapeutic trials in Duchenne Muscular Dystrophy. Evaluation of the patients: proposal for a protocol. Ital J Neurol Sci Suppl 3:133–136Google Scholar
  22. 22.
    D’Amicis A, Sette S, Turrini A, Battistini N, Carbini L, Giacchi M, Leonardi F, Sculati O, Castaldi N (2004) Assunzione di calcio alimentare nei bambini italiani. Riv Sci Aliment 3:99–106Google Scholar
  23. 23.
    Wang Q, Alén M, Nicholson P, Suominen H, Koistinen A, Kröger H, Cheng S (2007) Weight-bearing, muscle loading and bone mineral accrual in pubertal girls–a 2-year longitudinal study. Bone 40:1196–1202CrossRefPubMedGoogle Scholar
  24. 24.
    McKay H, Smith E (2008) Winning the battle against childhood physical inactivity: the key to bone strength? J Bone Miner Res 23:980–985CrossRefPubMedGoogle Scholar
  25. 25.
    Boot AM, de Ridder MAJ, Pols HAP, Krenning EP, de Muinck Keizer-Schrame SMPF (1997) Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab 82:57–62CrossRefPubMedGoogle Scholar
  26. 26.
    Ward K, Alsop C, Caulton J, Rubin C, Adams J, Mughal Z (2004) Low magnitude mechanical loading is osteogenic in children with disabling conditions. J Bone Miner Res 19:360–369CrossRefPubMedGoogle Scholar
  27. 27.
    Montgomery E, Pennington C, Isales CM, Hamrick MW (2005) Muscle-bone interactions in dystrophic-deficient and myostatin-deficient mice. Anat Rec 286A:814–822CrossRefGoogle Scholar
  28. 28.
    Talim B, Malaguti C, Gnudi S, Politano L, Merlini M (2002) Vertebral compression in Duchenne muscular dystrophy following deflazacort. Neuromuscul Disord 12:294–295CrossRefPubMedGoogle Scholar
  29. 29.
    Bothwell JE, Gordon KE, Dooley JM, Mac Sween J, Cummings EA, Salisbury S (2003) Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr 42:353–356CrossRefGoogle Scholar
  30. 30.
    Larson C, Henderson RC (2000) Bone mineral density and fractures in boys with Duchenne muscular Dystrophy. J Pediatr Orthop 20:71–78CrossRefPubMedGoogle Scholar
  31. 31.
    Vestergaard P, Glerup H, Steffensen BF, Rejnmark L, Rahbek J, Mosekilde L (2001) Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. J Rehabil Med 33:150–155CrossRefPubMedGoogle Scholar
  32. 32.
    McDonald DG, Kinali M, Gallagher AC, Mercuri E, Muntoni F, Roper H, Jardine P, Jones DH, Pike MG (2002) Fracture prevalence in Duchenne muscular dystrophy. Develop Med & Child Neurol 44:695–698CrossRefGoogle Scholar
  33. 33.
    Greer FR, Krebs NF, and the Committee on Nutrition (2006) Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 117:578–585CrossRefPubMedGoogle Scholar
  34. 34.
    Chevalley T, Bonjour J-P, Ferrari S, Hans D, Rizzoli R (2005) Skeletal site selectivity in the effects of calcium supplementation on areal bone mineral density gain: a randomized, double-blind, placebo-controlled trial in prepubertal boys. J Clin Endocrinol Metab 90:3342–3349CrossRefPubMedGoogle Scholar
  35. 35.
    Matkovic V, Landoll JD, Badenhop-Stevens NE, Ha EY, Crncevic-Orlic Z, Li B, Goel P (2004) Nutrition influences skeletal development from childhood to adulthood: a study of hip, spine, and forearm in adolescent females. J Nutr 134:701S–705SPubMedGoogle Scholar
  36. 36.
    Haddad JG, Rojanasathit S (1976) Acute administration of 25-hydroxycholecalciferol in man. J Clin Endocrinol Metab 42:284–290CrossRefPubMedGoogle Scholar
  37. 37.
    Pietrek J, Otto-Buczkowska E, Kokot F, Karpiel R, Cekański A (1980) Concentration of 25-hydroxyvitamin D in serum of infants under the intermittent high-dose vitamin D3 prophylactic treatment. Arch Immunol Ther Exp 28:805–814Google Scholar
  38. 38.
    Söderpalm AC, Magnusson P, Ahlander AC, Karlsson J, Kroksmark AK, Tulinius M, Swolin-Eide D (2007) Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord 17:919–928CrossRefPubMedGoogle Scholar
  39. 39.
    Klein RG, Arnaud SB, Gallagher JC, DeLuca HF, Riggs BL (1977) Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 60:253–259CrossRefPubMedGoogle Scholar
  40. 40.
    Willett AM (2005) Vitamin D status and its relationship with parathyroid hormone and bone mineral status in older adolescents. Proc Nutr Soc 64:193–203CrossRefPubMedGoogle Scholar
  41. 41.
    Harkness LS, Cromer BA (2005) Low levels of 25-hydroxy vitamin D are associated with elevated parathyroid hormone in healthy adolescent females. Osteoporos Int 16:109–113CrossRefPubMedGoogle Scholar
  42. 42.
    Brody BA, Dickey N, Ellenberg SS, Heaney RP, Levine RJ, O'Brien RL, Purtilo RB, Weijer C (2003) Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis? J Bone Miner Res 18:1105–1109CrossRefPubMedGoogle Scholar
  43. 43.
    Hawker GA, Ridout R, Harris VA, Chase CC, Fielding LJ, Biggar WD (2005) Alendronate in the treatment of low bone mass in steroid-treated boys with Duchenne’s muscular dystrophy. Arch Phys Med Rehabil 86:284–288CrossRefPubMedGoogle Scholar
  44. 44.
    Bishop N, Braillon P, Burnham J, Cimaz R, Davies J, Fewtrell M, Hogler W, Kennedy K, Mäkitie O, Mughal Z, Shaw N, Vogiatzi M, Ward K, Bianchi ML (2008) Dual-energy X-ray aborptiometry assessment in children and adolescents with diseases that may affect the skeleton: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 11:29–42CrossRefPubMedGoogle Scholar
  45. 45.
    Shaw NJ, Bishop NJ (2005) Bisphosphonate treatment of bone disease. Arch Dis Child 90:494–499CrossRefPubMedGoogle Scholar
  46. 46.
    Bachrach LK, Ward LM (2009) Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 94:400–409CrossRefPubMedGoogle Scholar
  47. 47.
    Marini JC (2009) Use of bisphosphonates in children-proceed with caution. Nat Rev Endocrinol 5:241–243CrossRefPubMedGoogle Scholar
  48. 48.
    Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, Galbiati E, Corona F, Luisetto G, Giuntini D, Picco P, Brandi ML, Falcini F (2000) Efficacy and safety of alendronate for the treatment of osteoporosis in different connective tissue diseases in children. Arthr Rheum 43:1960–1966CrossRefGoogle Scholar
  49. 49.
    Biggar WD, Bachrach LK, Henderson RC, Kalkwarf H, Plotkin H, Wong BL (2005) Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord 15:80–85CrossRefPubMedGoogle Scholar
  50. 50.
    Quinlivan R, Roper H, Davie M, Shaw NJ, McDonagh J, Bushby K (2005) Report of muscular dystrophy campaign workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscul Disord 15:72–79CrossRefPubMedGoogle Scholar
  51. 51.
    Bachrach LK (2005) Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. Neuromuscul Disord 15:86–87CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010

Authors and Affiliations

  • M. L. Bianchi
    • 1
    Email author
  • L. Morandi
    • 2
  • E. Andreucci
    • 2
  • S. Vai
    • 1
  • J. Frasunkiewicz
    • 3
  • R. Cottafava
    • 1
  1. 1.Centro Malattie Metaboliche OsseeIstituto Auxologico Italiano IRCCSMilanItaly
  2. 2.U.O. Patologie Muscolari e NeuroimmunologiaFondazione Istituto Neurologico C. Besta IRCCSMilanItaly
  3. 3.Department of Propedeutic Pediatrics and Bone Metabolic DiseasesMedical University of LodzLodzPoland

Personalised recommendations